

## TiGenix publishes transparency notification pursuant to Article 14 of the Law of May 2, 2007

**Leuven (Belgium) – May 31, 2013** – TiGenix NV (Euronext Brussels: TIG) publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

It concerns a notification by the related companies Genetrix Life Sciences A.B. (with address at Kungängsgatan 17-19, 753 22 Uppsala, Sweden), Genetrix SL and CX EBIP Agreement SLU (both with address at Plaza de la Encina nº 10-11, núcleo 1, planta 3ª, CP 28760 Tres Cantos, Madrid, Spain), regarding the crossing below the lowest threshold of 3% on May 28, 2013 by the group as a whole following transfers of shares by both Genetrix Life Sciences A.B. and CX EBIP Agreement SLU (who previously held respectively 2,581,501 and 1,905,144 shares, or together 4,486,645 shares), after which the participations of these companies were as follows (compared to the denominator of 100,288,586 shares):

- Genetrix Life Sciences A.B.: 1,136,629 shares (1.13%),
- Genetrix SL: no shares (0%),
- CX EBIP Agreement SLU: 1,839,437 shares (1.83%),
- Total: 2,976,066 shares (2.97%).

The chain of controlled undertakings through which the holdings are effectively held, is as follows: Genetrix SL controls Genetrix Life Sciences A.B. and Genetrix Life Sciences A.B. controls CX EBIP Agreement SLU.

For further details regarding these notifications, we refer to our website: <http://www.tigenix.com/en/page/26/shareholders>.

**For more information:**

Eduardo Bravo  
Chief Executive Officer  
[eduardo.bravo@tigenix.com](mailto:eduardo.bravo@tigenix.com)

Claudia D'Augusta  
Chief Financial Officer  
[claudia.daugusta@tigenix.com](mailto:claudia.daugusta@tigenix.com)

Hans Herklots  
[hans.herklots@tigenix.com](mailto:hans.herklots@tigenix.com)  
+32 16 39 60 97

# TIGENIX

## **About TiGenix**

*TiGenix NV (Euronext Brussels: TIG) is a leading European cell therapy company with a marketed cell therapy product for cartilage repair, ChondroCelect®, and a strong pipeline with clinical stage allogeneic adult stem cell programs for the treatment of autoimmune and inflammatory diseases. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands). For more information please visit [www.tigenix.com](http://www.tigenix.com).*